ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,561 to 4,580 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Prolonged RBC Storage vs Short RBC Storage: Effect of RBC Age on Occurrence of Pulmonary Events.113 of 686

106 of 701

1.4 points

-2.5 to 5.2

1,387NCT00458783

Red Cell Storage Duration and Outcomes in Cardiac Surgery

Prolonged RBC Storage vs Short RBC Storage: deaths from any cause23 of 686

15 of 701

1.2 points

-0.5 to 3.0

1,387NCT00458783

Red Cell Storage Duration and Outcomes in Cardiac Surgery

Prolonged RBC Storage vs Short RBC Storage: serious adverse events360 of 686

362 of 701

0.8 points

-4.4 to 6.1

1,387NCT00458783

Red Cell Storage Duration and Outcomes in Cardiac Surgery

Arm A: EC-T vs Arm B: ET-X: Number of Participants With Disease-free Survival (DFS) Event127 of 669

170 of 715

-4.8 points

-9.1 to -0.5

1,384NCT00129935

EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer

Arm A: EC-T vs Arm B: ET-X: deaths from any cause70 of 669

83 of 715

-1.1 points

-4.5 to 2.2

1,384NCT00129935

EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer

Arm A: EC-T vs Arm B: ET-X: Number of Participants With Overall Survival (OS) Event70 of 669

83 of 715

-1.1 points

-4.5 to 2.2

1,384NCT00129935

EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer

Arm A: EC-T vs Arm B: ET-X: serious adverse events111 of 669

138 of 715

-2.7 points

-6.7 to 1.4

1,384NCT00129935

EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer

Nitric Oxide Releasing Solution vs Placebo: Number of Participants Reporting Safety Concerns.129 of 690

130 of 694

-0.0 points

-4.1 to 4.1

1,384NCT05109611

Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection

Nitric Oxide Releasing Solution vs Placebo: Number of Participants Requiring Medical Services.1 of 690

0 of 694

0.1 points

-0.4 to 0.8

1,384NCT05109611

Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection

Nitric Oxide Releasing Solution vs Placebo: Number of Participants With a COVID-19 Infection.2 of 690

2 of 694

0.0 points

-0.8 to 0.8

1,384NCT05109611

Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection

Nitric Oxide Releasing Solution vs Placebo: serious adverse events1 of 690

0 of 694

0.1 points

-0.4 to 0.8

1,384NCT05109611

Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection

Boostrix Group vs Adacel Group: Number of Subjects With Anti-D Antibody Concentrations ≥ Protocol Specified Cut-off857 of 934

425 of 449

-2.9 points

-5.5 to 0.1

1,383NCT00489970

Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9

Restrictive vs Liberal: A Composite Endpoint of All-cause Mortality, MI, Coronary Revascularization, Acute Renal Failure, or Postoperative Ischemic Stroke45 of 703

33 of 680

1.5 points

-0.9 to 4.0

1,383NCT03229941

Transfusion Trigger After Operations in High Cardiac Risk Patients

DDLPS Patients With 1L Treatment at Index Date (Cohort 1) vs DDLPS Patients Without 1L Treatment at Index Date (Cohort 2): deaths from any cause175 of 275

423 of 1,106

25.4 points

18.9 to 31.5

1,381NCT06115681

Real-world Study of Dedifferentiated Liposarcoma Patients in China

Reimbursement for Smoking Cessation Therapy (SCT) vs No Reimbursement for SCT: serious adverse events35 of 696

25 of 684

1.4 points

-0.8 to 3.6

1,380NCT00818207

Impact Of Smoking Cessation Treatment Reimbursement On The Quit Rates In Smokers Motivated To Quit

Boostrix Group vs Adacel Group: Number of Subjects With Anti-T Antibody Concentrations ≥ Protocol Specified Cut-off899 of 937

440 of 442

-3.6 points

-5.1 to -2.0

1,379NCT00489970

Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9

Arm A: EC-T vs Arm B: ET-X: The Number of Participants Who Experienced Adverse Events (AE)665 of 667

699 of 711

1.4 points

0.3 to 2.6

1,378NCT00129935

EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer

CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) vs Usual Care: Number of Patients With Optimal Glucose Control141 of 659

159 of 719

-0.7 points

-5.1 to 3.7

1,378NCT03890588

Chronic Kidney Disease Clinical Decision Support

Edoxaban vs Vitamin K Antagonist (VKA): deaths from any cause83 of 693

78 of 684

0.6 points

-2.8 to 4.0

1,377NCT02943785

Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)

Edoxaban vs Vitamin K Antagonist (VKA): serious adverse events388 of 693

372 of 684

1.6 points

-3.6 to 6.8

1,377NCT02943785

Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=229"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=229

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00458783-d27ffc31",
        "title": "Prolonged RBC Storage vs Short RBC Storage: Effect of RBC Age on Occurrence of Pulmonary Events.",
        "summary": "113 of 686 against 106 of 701; risk difference 1.4 points, 95% interval -2.5 to 5.2; NCT00458783, Red Cell Storage Duration and Outcomes in Cardiac Surgery",
        "record": "/library/comparisons/NCT00458783-d27ffc31",
        "nct_id": "NCT00458783",
        "kind": "outcome",
        "participants": 1387,
        "risk_difference": {
          "value": 0.013510478574963708,
          "lower": -0.02492263872583205,
          "upper": 0.0520159103541047
        },
        "group_1": "113 of 686",
        "group_2": "106 of 701",
        "difference": "1.4 points",
        "interval": "-2.5 to 5.2",
        "trial_title": "Red Cell Storage Duration and Outcomes in Cardiac Surgery"
      },
      {
        "id": "NCT00458783-deaths",
        "title": "Prolonged RBC Storage vs Short RBC Storage: deaths from any cause",
        "summary": "23 of 686 against 15 of 701; risk difference 1.2 points, 95% interval -0.5 to 3.0; NCT00458783, Red Cell Storage Duration and Outcomes in Cardiac Surgery",
        "record": "/library/comparisons/NCT00458783-deaths",
        "nct_id": "NCT00458783",
        "kind": "deaths",
        "participants": 1387,
        "risk_difference": {
          "value": 0.01212969393993587,
          "lower": -0.005419124148746301,
          "upper": 0.030443145217861532
        },
        "group_1": "23 of 686",
        "group_2": "15 of 701",
        "difference": "1.2 points",
        "interval": "-0.5 to 3.0",
        "trial_title": "Red Cell Storage Duration and Outcomes in Cardiac Surgery"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=230",
  "request_id": "9_o_WFX3c8XR_imk"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

Instruments

The conductscience.com catalog

One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.

Drugs and targets

Open Targets

One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.

Diseases

Open Targets

One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.

Companies

ClinicalTrials.gov

One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.

Cell lines

Cellosaurus

One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.

Journal index

PubMed and NLM's journal list

One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?